Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patientâ€™s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/08/26	US$0.2576	-8.21%	2,757
13/08/26	US$0.2807	+3.94%	8,103

Delayed Quote OTC Markets

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 19:04:19 14/08/2026 BST			5-day change	1st Jan Change
0.2576 ^USD	-8.21%		-8.21%	-62.13%

08-07	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	849K 727K 678K 622K 1.17M 81.22M 1.19M 8.04M 3.14M 40.7M 3.19M 3.12M 135M	P/E 2024	-0.22x	P/E 2025	-0.73x
Enterprise Value	-2.01M -1.72M -1.6M -1.47M -2.76M -192M -2.82M -19.01M -7.41M -96.2M -7.53M -7.37M -319M	EV / Sales 2024	-	EV / Sales 2025	-491,128x
Free-Float	86.49%	Yield 2024 *	-	Yield 2025	-

08-07	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-23	Avenue Therapeutics, Inc. Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	CI
11-13	Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI
11-06	Axsome Therapeutics acquires AZD7325, a selective GABA-A modulator for treatment of epilepsy	RE
11-05	Axsome Therapeutics, Inc. entered into stock purchase agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $83.3 million.	CI
14/08/25	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/05/25	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
30/04/25	Avenue Therapeutics, Inc. and Annji Pharmaceutical Co., Ltd. Enters into A License Termination	CI
31/03/25	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

02-23	Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	AQ
11-06	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ
14/11/24	Avenue Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Form 8 K	PU
14/11/24	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
09/10/24	Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit	AQ

Avenue Therapeutics, Inc. Share Price

Stocks

ATXI

US05360L4032

Biotechnology & Medical Research

Valuation: Avenue Therapeutics, Inc.

Chart: Avenue Therapeutics, Inc.

Latest news : Avenue Therapeutics, Inc.

Analysts' recommendations: Avenue Therapeutics, Inc.

Press Releases: Avenue Therapeutics, Inc.

News in other languages: Avenue Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avenue Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

18/04/23	MÄRKTE USA/Anleger bleiben in Deckung und warten Quartalszahlen ab
18/04/23	MÄRKTE USA/Anleger mit Blick auf Berichtssaison zurückhaltend
18/04/23	MÄRKTE USA/Uneinheitlich - Goldman Sachs bremst Dow
18/04/23	MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten
09/03/23	Wall Street hard onderuit in aanloop naar banencijfer

1 day	-8.21%
1 week	-8.21%
Current month	-33.56%
1 month	+3.04%
3 months	-8.00%
6 months	+71.73%
Current year	-62.13%

1 month	0.26	0.52
Current year	0.15	0.79
1 year	0.15	0.97
3 years	0.15	74.99
5 years	0.15	2,081.25
10 years	0.15	13,882.3

Manager	Title	Age	Since
Alexandra MacLean CEO	Chief Executive Officer	59	31/07/2022
David Jin CEO	Chief Executive Officer	36	30/03/2022
Jaclyn Jaffe IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Lindsay Rosenwald CHM	Chairman	71	08/02/2015
Neil Herskowitz BRD	Director/Board Member	69	31/07/2015
Jay Kranzler CHM	Chairman	68	06/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/01/26	FORTRESS BIOTECH, INC.	Free	Company	111,209	3.4934%
31/03/25	FORTRESS BIOTECH, INC.	Free	Company	33,724	1.6419%
31/12/24	FORTRESS BIOTECH, INC.	Other	Company	294,800	15.4214%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVENUE THERAPEUTICS, INC.	-8.21%	-8.21%	-56.34%	-99.64%	849K
WUXI APPTEC CO., LTD.	+2.38%	+3.43%	+82.88%	+115.89%	73.96B
ARGENX SE	-0.29%	+20.73%	+53.06%	+93.29%	64.66B
INSMED INCORPORATED	-4.27%	-0.99%	-3.38%	+475.61%	27.32B
BIONTECH SE	-1.97%	+20.38%	-0.37%	+0.48%	27.86B
WUXI BIOLOGICS (CAYMAN) INC.	+2.44%	+12.43%	+62.04%	+27.51%	25.97B
GENMAB A/S	-0.16%	+5.73%	+38.71%	-12.79%	19.98B
PHARMAESSENTIA CORPORATION	-1.79%	-4.84%	+239.54%	+414.48%	17.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.13%	+3.75%	+19.00%	+535.29%	16.24B
EXELIXIS, INC.	-1.29%	+6.09%	+41.81%	+154.45%	13.3B
Average	-1.22%	+5.57%	+47.69%	+170.46%	28.71B
Weighted average by Cap.	+0.01%	+8.21%	+59.14%	+160.94%

	2024	2025
Net sales	-	1.4 1.2 1.12 1.03 1.93 134.34 1.97 13.31 5.19 67.33 5.27 5.16 222.89
Net income	-11.65M -9.98M -9.31M -8.54M -16.05M -1.11B -16.37M -110M -43.05M -559M -43.75M -42.8M -1.85B	-2.91M -2.49M -2.32M -2.13M -4.01M -278M -4.09M -27.57M -10.75M -139M -10.92M -10.69M -462M
Net Debt	-2.59M -2.22M -2.07M -1.9M -3.57M -248M -3.64M -24.58M -9.58M -124M -9.74M -9.53M -412M	-2.86M -2.44M -2.28M -2.09M -3.93M -273M -4.01M -27.06M -10.55M -137M -10.72M -10.49M -453M